Target Research Articles

  1. What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment 3/23/2026

    Insights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.

  2. Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery 3/19/2026

    We caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.

  3. Proteomics Biomarkers Beyond Blood 3/16/2026

    Effective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.

  4. The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era 3/5/2026

    The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.

  5. Proteomics Tools: A Resurrection 3/4/2026

    For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.

  6. Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models 3/3/2026

    Alice Stanton, PhD, member of the faculty, Harvard Medical School, engineered the first 3D immuno-glial-neurovascular human multicellular integrated brain (miBrain) model. In this video spotlight interview, Dr. Stanton shares her journey into science and neural organoid research.

  7. Elusive Success Of CDK2: Why That May Be Changing 3/2/2026

    Cyclin-dependent kinase 2 has eluded clinical validation, but that may be changing.

  8. Structural Biology Wages War On HIV And The Pandemics Of Tomorrow 2/27/2026

    Imagine waking up to news of another outbreak — masks, lockdowns, lives upended. But what if we could stop the next one before it starts? 

  9. The Matchmaker Modality: Engineering Event-Driven Pharmacology With Induced Proximity 2/24/2026

    Induced proximity has evolved into a versatile platform with the potential to change drug discovery, but challenges still remain.

  10. A State Of Stress: Developing Therapeutics Rooted In Cell Behavior 2/24/2026

    We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.